has been looking for. It's rapid, and it's reliable. It follows disease progression via T-cells. It doesn't replace normal differential diagnoses, it augments and supports them by measuring the levels of immune response, imagine if CCSVI candidates had this test both pre and post op and into the future.
If indeed, negating the effects of reflux and damage via the venous system could be objectively shown to have slowed down or stopped the autoimmune response, well then we have the objective, scientific PROOF of the benefits of CCSVI treatment we've been waiting for. http://www.selectscience.net/product-news/Lophius-Biosciences-Gmbh/Lophius-Biosciences-Collaboration-Develops-Test-for-Diagnosis-and-Monitoring-of-Multiple-Sclerosis/?&artID=29310
Lophius Biosciences Collaboration Develops Test for Diagnosis and Monitoring of Multiple Sclerosis 21 Jun 2013
Bionamics GmbH, the coordinator of the NEU² consortium, and Lophius Biosciences GmbH have announced that Lophius Biosciences has joined the NEU² program with a project addressing the development of T-Track® MS as a novel blood-based diagnostic test supporting the initial diagnosis of multiple sclerosis (MS) and enabling the monitoring of MS disease progression. This new project is to last for about two years with a funding of > 350.000 EUR proportionally supplied by The Federal Ministry of Education and Research (BMBF) under the BioPharma initiative.
Lophius Biosciences is a leading developer of innovative T cell based diagnostic test systems. One of the company’s platform technologies, the “Reverse T Cell Technology (RTT)”, represents a novel strategy for the diagnosis of T cell-mediated diseases. In contrast to available methods, RTT exploits the maturation processes induced in antigen presenting cells (APC) via a specific interaction with activated T helper (Th) cells thus representing an indirect measure for activated Th cells. Due to the high specificity of RTT for activated Th cells, the intended use of the RTT assay is the reliable detection of disease-specific activated Th cells as a novel biomarker for the diagnosis and monitoring of ongoing autoimmune diseases such as MS. The T-Track® MS test is aimed to fulfill unmet clinical needs offering a blood-based rapid and reliable differential diagnosis of MS complementary to the today’s state of the art clinical and MRT based diagnosis. Initial data from a collaboration between Lophius Biosciences and the Clinic and Policlinic for Neurology, University of Regensburg, and the Institute for Neuroimmunology and Clinical MS Research, Center for Molecular Neurobiology Hamburg, demonstrated preliminary clinical proof of principle for this MS test.
Dr. Michael Lutz and Prof. Dr. Ralf Wagner, Managing Directors of Lophius Biosciences commented: “We are very pleased to join the NEU² consortium. Both the opportunity to interact with leading experts in the MS field as well as the substantial funding will accelerate the development of our highly innovative T cell based diagnostic T-Track® MS test kit and help Lophius to initiate a broader clinical discovery and development program.”
Dr. Timm Jessen, CEO of Bionamics GmbH and founder of NEU², about the further expansion of the NEU² consortium: “With Lophius Biosciences we could attract an attractive new partner for the consortium. Its expertise in the diagnostic area will complement our expertises within NEU², also to the benefit of our current consortium members.”